NCT00149565|CompletedPhase 3
Phase Ⅲ Randomized Trial in Postoperative Hepatocellular Carcinoma
Hepatocellular Carcinoma Postoperative Adjuvant Therapy Disease Committee of Taiwan Cooperative Oncology Group
Loading search results
Hepatocellular Carcinoma Postoperative Adjuvant Therapy Disease Committee of Taiwan Cooperative Oncology Group
Sponsor study identifier
interventional
268
1 country
1
Study Start
October 1997
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
July 2005
Date type not reportedThis date has not been verified as actual or estimated.
\* OBJECTIVES
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2005
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 1997
Date type not reportedThis date has not been verified as actual or estimated.
July 2005
Date type not reportedThis date has not been verified as actual or estimated.
September 7, 2005
Actual (reported)September 8, 2005
Actual (reported)134 patients for each of the two treatment arms are needed.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Chang Gung Memorial Hospital
Taoyuan, 333, Taiwan
Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, Wu CC, Mok KT, Chen CL, Lee WC, Chau GY, Chen YS, Lui WY, Hsiao CF, Whang-Peng J, Chen PJ; Disease Committee of Adjuvant Therapy for Postoperative Hepatocellular Carcinoma, Taiwan Cooperative Oncology Group, National Health Research Institutes, Zhunan, Taiwan. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg. 2012 Jan;255(1):8-17. doi: 10.1097/SLA.0b013e3182363ff9.
Li-Tzong Chen, Ph.D.
Hepatocellular Carcinoma Postoperative Adjuvant Therapy Disease Committee of TCOG
Pei-Jer Chen, Ph.D.
Hepatocellular Carcinoma Postoperative Adjuvant Therapy Disease Committee of TCOG
First Submitted
September 7, 2005
First Posted
September 8, 2005
Study Start
October 1997
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
July 2005
Date type not reportedAdjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression
Contact the study team to confirm eligibility.
This date has not been verified as actual or estimated.
Last Updated
December 16, 2005
Record last verified: 2004-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: